Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike …


Sumary of Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike price for at least 4 years:

  • Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year for the company’s FDA-approved Alzheimer’s disease drug aducanumab is “fair.”.
  • That being said, the Massachusetts-based biotech company has vowed to not increase the price of the medication, which is marketed under the name Aduhelm, for the next four years, Vounatsos said..
  • and will also allow Biogen to further invest in its pipeline of medicines for other diseases, he said during an interview with CNBC’s “Power Lunch.”.
  • He added the company is working closely with federal health insurance program Medicare as well as private insurers..
  • Shares of Biogen surged as high as 60% on Monday after the Food and Drug Administration announced it had approved the company’s drug for the disease..
  • Biogen said Monday that aducanumab’s list price is $56,000 per year, which was higher than the $10,000 to $25,000 price some analysts were expecting…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.